Live tape
Top 8, mentions 7d6,968META1,793 mentions▲ +0.06GOOGL1,433 mentions▲ +0.03NVDA885 mentions▲ +0.09TSLA655 mentions▲ +0.05MSFT580 mentions▲ +0.06SPY571 mentions▲ +0.03AMZN554 mentions▲ +0.04AAPL497 mentions▲ +0.07

Equity · Healthcare

MRVI

NASDAQ

Maravai LifeSciences Holdings, Inc.

$7.65 +3.80% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 24, 2026
Price · Chart
Our own end-of-day closes 59 sessions
$10 $4 2 Jul 24 Sep

The line runs $6 on 2 July through $7.65 on 24 September, on a scale from $4 to $10. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of MRVI over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 59 sessions over that window: $6 on 2 July 2026 through $7.65 on 24 September 2026.

Market cap $1.1B
52-week range $2.69 – $9
Avg volume 308.8K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 24, 2026

MRVI insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 8 Sep 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 5

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Sep 2026 Brust Bernd Chief Executive Officer Tax withheld 29,250 $214K
31 Aug 2026 Asarpota Rajesh Chief Financial Officer Tax withheld 5,465 $42K
10 Aug 2026 Brust Bernd Chief Executive Officer Tax withheld 29,250 $182K
30 Jul 2026 Asarpota Rajesh Chief Financial Officer Tax withheld 5,465 $36K
08 Jul 2026 Brust Bernd Chief Executive Officer Tax withheld 29,250 $173K

MRVI reported financials

SEC EDGAR XBRL

MRVI reported revenue of $185.7M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$130.8M.

Figure Reported Period
Revenue $185.7M 31 Dec 2025 fiscal year
Net income −$130.8M 31 Dec 2025 fiscal year
Diluted EPS −$0.90 31 Dec 2025 fiscal year
Total assets $603.7M 30 Jun 2026 at period end
Total equity $204.6M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

MRVI earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.08 $51M
31 Mar 2026 Q1 2026 $-0.02 $66M
31 Dec 2025 FY 2025 $-0.90 $186M
30 Sep 2025 Q3 2025 $-0.18 $42M
30 Jun 2025 Q2 2025 $-0.27 $47M
31 Mar 2025 Q1 2025 $-0.21 $47M
31 Dec 2024 FY 2024 $-1.05 $259M
30 Sep 2024 Q3 2024 $-0.68 $69M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

MRVI institutional holders

SEC Form 13F

9 of the 45 institutional funds we track reported a MRVI position for the quarter ended 30 Jun 2026 — a combined $131.4M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Millennium Management Added +294.6% shares 6,508,220 $40.6M
Renaissance Technologies Held (±25%) +8.0% shares 4,606,491 $28.7M
Two Sigma Investments Added +42.8% shares 2,255,820 $14.1M
Citadel Advisors Added +43.0% shares 2,122,598 $13.2M
Point72 Asset Management Trimmed −37.4% shares 2,005,579 $12.5M
Tudor Investment Corp Added +365.9% shares 1,849,079 $11.5M
Marshall Wace Trimmed −29.3% shares 1,471,477 $9.2M
Man Group New position 158,429 $989K
AQR Capital Management Held (±25%) +2.8% shares 84,821 $529K

Source: SEC EDGAR 13F filings

MRVI fails-to-deliver

SEC CNS data

On 03 Sep 2026, 7,459 shares of MRVI failed to deliver (about $55K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
03 Sep 2026 7,459 $55K 0.005%
02 Sep 2026 1,319 $10K 0.001%
24 Aug 2026 500 $4K <0.001%
17 Aug 2026 524 $3K <0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in MRVI

STOCK Act disclosures

The most recent congressional trade disclosed in MRVI is a sale by Daniel S. Goldman (house, NY), dated 10 Apr 2023.

Date Member Type Amount
10 Apr 2023 filed 19 May 2023 Daniel S. Goldman house · Democrat–NY Sale $1K–$15K

Source: U.S. House of Representatives financial disclosures